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Statement of Thesis
This thesis should be used as a guide to understand how neuroinflammation in the brain
underlies the pathology observed in Alzheimer’s disease. I will aim to outline how healthcare
practitioners diagnose and treat their patients, providing linkages between how
neuroinflammatory processes can be targeted for future therapies. Additionally, I will discuss
the psychological effects of this progressive and deadly disease and assess how patients and
families cope with this prognosis.
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Introduction
Alzheimer’s disease (AD) is a progressive and deadly disease that is marked by cognitive
decline, including memory impairments and language disturbances, as well as the development
of senile plaques and neurofibrillary tangles (Zarow et al., 2007). Approximately 70 million
people worldwide have been diagnosed with Alzheimer’s disease; this number is projected to
increase to approximately 370 million people by the year 2050 (Schachter, 2000). Along with a
diagnosis of Alzheimer’s disease, the patient’s lives as well as the lives of the patient’s family
are forever altered. Like so many others, my family felt the grief and anxiety that accompanies a
loved-one’s diagnosis of Alzheimer’s disease.
Throughout the beginning of my childhood, my family would notice that my
grandmother, who I lovingly called Nana, started to exhibit memory loss. She struggled to
remember my name, as well as the names of our other family members, but this was easily
dismissed, as my mother is one of six children, all of whom are married with children, and most
of their children have children as well. In 2012, the lives of my family would be altered forever.
One day, my Grandpa Bill took a fall that resulted in a severe head injury. As a result, Nana
wanted to be by his side while he stayed in the hospital. As my grandmother drove this familiar
route to the hospital, she unfortunately drove off the road. Fortunately, she was not severely
injured; however, my family felt it best that Nana would permanently retire from driving.
Several days later, Grandpa Bill unfortunately passed away with Nana by his side. As my family
grieved our loss, we continued to worry about the state of my grandmother. She was now living
alone and had no means to drive to see any of her family members. Ultimately, my family
decided it would be best for Nana to be moved to an assisted living building at a retirement
community, of which she already resided. In her new living arrangements, she was receiving
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more medical attention; the nurses noted that she was struggling to eat and began having
hallucinations. She also began telling outrageous stories, likely as a result of her cognitive
decline.
Finally, she saw a physician who diagnosed her with dementia, likely resulting from
Alzheimer’s disease. AD is the most frequent cause of dementia. Although the average survival
duration is approximately 5-8 years after clinical AD diagnosis, the pre-dementia phase could
potentially last decades; however, there is no way to establish the onset of this phase. Within the
pre-dementia stage, mild cognitive impairment (MCI) is often a symptom. This impairment can
result in frustration and in some cases, severe depression; however, the mild cognitive
impairment does not otherwise seem to significantly impact Activities of Daily Life (ADL) at
this early stage in the disease (Förstl et al., 1999). Individuals in the pre-dementia stage tend to
struggle to identify objects and additionally show decreased word fluency. Spatial disorientation
is a common symptom; therefore, patients who even mildly suffer from AD should not drive.
After the disease has progressed, individuals may exhibit aggression and violence, commonly
due to confusion. Many patients additionally suffer from extreme apathy and exhaustion,
furthering aggressive behaviors (Förstl et al., 1999). My grandmother exhibited many of these
same symptoms, leading to her dementia diagnosis. We were devastated by her diagnosis, but at
least had an understanding as to why she was struggling to eat and had notable memory deficits.
Over the course of several years, Nana continued to decline. Luckily, Nana lived nearby, so my
family visited her as often as we could, bringing her favorite meals and new clothes at each visit.
In the winter of 2019, before heading back to DePauw University for spring semester, my
brother and I saw my grandmother for the last time. At our last visit, not only did Nana not
recall my name nor my brother’s, she clearly did not recognize us at all; she became extremely
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nervous when my brother and I entered her room. Unsure of what to do, I called my mom,
hoping that Nana would recognize her daughter’s voice, easing her anxiety and nervousness.
Eventually, my brother and I were able to give Nana a hug and a kiss goodbye, hoping to see her
soon. She unfortunately died that Spring, nine days shy of her ninety-second birthday.
Nana faced a devastating uphill battle against a deadly disease for which there is
currently no cure. She was an inspiration to her 6 children, 14 grandchildren, and 15 great
grandchildren to never give up and to never lose hope; she fought until the very end and never let
her disease define her. She continued to enjoy the company of loved ones and always beamed
with joy upon hearing the successes of her family, such as receiving job opportunities, getting
into college, or winning a soccer game. My grandmother’s strength and never-failing hope has
inspired me to want to work in healthcare; I hope to treat patients with the same encouragement
and hope that my grandmother showed every day. My grandmother’s story is likely a familiar
tale; patients and loved ones undergo much the same story. Cognitive decline and changes in
personality, among many other symptoms, mark a drastic change in the patient’s quality of life,
leaving patients and families feeling helpless. The inflammatory processes that occurred in her
body as a result of AD resulted in the perpetual cycle of inflammation, furthering the progression
of this disease. Ultimately, I hope that future advancements will find a cure, allowing for
increased quality of life, rather than live with a known death sentence.
Unfortunately, the story remains unchanged; clinicians aim to treat their patients as best
as they can, but the few available treatments merely delay the progression of Alzheimer’s disease
by a few years at best (Weller et al., 2018). Thus, it is ideal that patients aim to mitigate their
chances of ever developing the disease to begin with. Our current understanding of the
neuroinflammatory processes involved in the onset of Alzheimer’s disease will hopefully allow
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for further research aimed at a cure, increasing the quality of life of patients diagnosed with
Alzheimer’s disease.

10

Early Understandings of Alzheimer’s Disease
Dementia and AD have been discussed by famous scientists, researchers, and profound
intellects for centuries, even before Alzheimer’s disease was defined in 1906. Around 3,000
B.C., Prince Ptah-Hotep governed a city in Egypt. He was known as a vizier, which was the
highest governing position in ancient Egypt, second to the pharaoh. Prince Ptah-Hotep was an
extremely wise and well-respected man; he spoke of fairness, kindness, and the rules of
etiquette. Additionally, he described the onset of old age, which he claimed brought
senility. Interestingly, senility is an outdated word used to describe people with AD or dementia,
so it is possible that Prince Ptah-Hotep was actually describing the symptoms of individuals with
AD, rather than the common occurrences of old age. He claims senility is marked by the
inability to remember the past, a change in personality, and an inability to properly taste
(Fontaine, 1981).
Although these are all common occurrences associated with aging, people with AD have
these same symptoms. Interestingly enough, the word ‘senility’ is an outdated term used to
describe people with AD or dementia; thus, it is possible that Prince Ptah-Hotep was actually
describing the symptoms of AD. Regardless, his writings and teachings are some of the oldest
known teachings regarding the topic of the elderly. Additionally, the Ebers Papyrus, an ancient
Egyptian medical analysis by an unknown author, describes the relationship between
cardiovascular illnesses and senile decay, which is interesting given that cardiovascular disease
is a risk factor for AD (Fontaine, 1981). Thoughts from Prince Ptah-Hotep and the writings from
the author of the Ebers Papyrus indicate that much was known about diseases, potentially
including AD.
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Terminology, such as the word ‘dementia’ has been known to exist since approximately
25 BC when Aulus Celsus used the term for the first time in his Treaty of Medicine. Celsus
described an individual who has dementia to exhibit “irrational imaginations…[and] the person
speaks irrationally” (Bán, 2019). Dementia is now recognized as a possible outcome of the
progression of AD; however, given the generality of the symptoms described by Celsus, it is
possible that he was again describing a patient suffering from AD. Regardless, it is evident that
wise scholars thousands of years ago were familiar with the common occurrences as one
progressed through different stages of life, leading to illnesses that can be identified as dementia
or AD.
Hippocrates, who has been deemed the “father of medicine,” has been credited with
being the first physician to ever describe epilepsy and pneumonia (Pappas et al., 2008). He
aimed to use logic in his everyday life to treat the mysterious symptoms that his patients
presented. In fact, he differed from many physicians during his time, such that he did not believe
illnesses were God-sent. Many physicians throughout this time believe that doctors were a sort
of punishment sent by God, whereas Hippocrates did not believe that God was punishing
individuals, but that patients were merely unfortunate to have developed such diseases.
Additionally, Hippocrates rejected the idea that the practice of medicine should be passed down
between family members; instead he opened the School of Kos where he taught medicine to
anyone who wanted to learn his popular medical techniques. Hippocrates changed the practice
of medicine, allowing for more people to be effectively treated during this time.
Hippocrates gave both specific and general advice to his patients, depending on the
patient’s symptoms. More generally speaking, he explained that “The most famous doctors cure
by changing the diet and lifestyle of their patient and, by using other substances. Such capable
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doctors have the knowledge and ability to use the therapeutic properties of most natural or manmade products” (Tsiompanous & Marketos, 2013). This advice still is beneficial today; we
know that eating habits, activity levels, sleep patterns, and other lifestyle choices are important
habits that contribute to an individual’s likelihood to develop certain diseases. This advice is
especially pertinent to individuals who want to mitigate their chances of developing chronic or
terminal illnesses, including AD; those who lead healthier lifestyles have a better chance of
offsetting their likelihood of developing AD. Additionally, Hippocrates “believed that there is
an association between mental health and intestinal flora imbalance” (Sochocka et al.,
2018). Over the past decade, Hippocrates' beliefs have led to research surrounding the
importance of a balanced gut microbiome. Now, it is understood that an imbalance in the gut
microbiome can cause illnesses, both chronic and acute, including AD (Sochocka et al.,
2018). However, Hippocrates believed that four humors governed the body. One of these
humors was associated with the temperament of melancholy. For Hippocrates “there was no
differentiation between dementia and chronic mental syndromes, as he classified all as
‘melancholy’” (Vatanabe et al., 2020); whereas today, we know there are differences between
depression, schizophrenia, AD, and other neurological illnesses, all of which Hippocrates would
have classified as ‘melancholy.’
Thus, it is evident that the concept of dementia was well-known throughout
history. Furthermore, it is evident even in popular literary novels that dementia was a known and
arguably feared illness. Many have hypothesized that William Shakespeare’s King Lear may
have suffered from dementia when King Lear states that “I fear I am not in my perfect mind.
Methinks I should know you, and know this man. Yet I am doubtful, for I am mainly ignorant.
What place this is, and all the skill I have remembers not these garments. Nor I know not where I
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did lodge last night” (Shakespeare, 1999). King Lear describes himself as unable to identify
familiar faces and even his whereabouts from the day prior. In the plot, King Lear even disowns
his favorite daughter; in this way, Shakespeare was likely emphasizing the intense shifts in mood
and personality, a common symptom of dementia or AD.
Later, in the 1800’s, Philippe Pinel began classifying different psychiatric
disorders. Similar to Hippocrates, Pinel made amazing breakthroughs within the medical
community, but in an entirely different way. He focused his research on “only those symptoms
and distinctive signs which are recognizable by the senses and which are not susceptible to vague
reasoning” (Woods & Carlson, 1961) indicating that he focused primarily on psychiatric
illnesses. Up until this point in time, patients who suffered from psychiatric disorders were
placed in psychiatric institutions, where they were commonly chained up and otherwise treated
poorly; these patients were deemed inhuman and were commonly feared by everyday
people. Through his years of research, he realized that these patients suffered from “insanity”
(Woods & Carlson, 1961), which he believed to be a disease, rather than a crime. He later
became the resident physician of two Paris asylums, due to his passions for understanding mental
illness.
A movement spread across Europe, leading to the unshackling and freeing of these
prisoners, allowing for the patients to undergo various therapies to treat their disorders. Through
his research he was able to classify mental disorders into five major groups: dementia, idiocy,
melancholia, mania with delirium, and mania without delirium (Vatanabe et al.,
2020). Specifically, Pinel referred to dementia as a “complete forgetting of any prior state,
prejudice of judgment, repeated acts of extravagance, all in a rapid succession, or in an
uninterrupted alternation of insulated ideas” (Vatanabe et al., 2020); these symptoms closely
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mirror the symptoms that have been used to describe individuals with dementia or AD
today. People with AD tend to exhibit memory loss, difficulty organizing thoughts, and extreme
changes in mood, all of which Pinel captured throughout his research.
Pinel’s dedication to understanding neurological illnesses allowed later physicians to be
better equipped to treat their patients with more care and compassion. Although descriptions of
dementia and AD have been discovered from as early as the time of the ancient Egyptians,
people who suffered from neurological illnesses, including dementia and AD, were often feared
and deemed as outsiders from society. Pinel led the movement allowing all patients to be treated
with an open mind, leading to better and more thorough treatment methods, and opening the
doors for future physicians, such as Jean-Etienne Dominique, to more thoroughly study the
illnesses identified by Pinel.
As Pinel’s student, Esquirol learned the importance of compassion and care towards
patients suffering from neurological illnesses. Esquirol helped to continue the reforms that Pinel
had set into motion; Esquirol introduced the Law on Alienated Persons of 1838 to ultimately
help to improve conditions in asylums and allow for better medical treatment. Additionally,
Esquirol further elaborated upon the definitions of various diseases, which had been previously
defined by Pinel. For dementia in particular, Esquirol reasoned that dementia should be defined
as follows: “the incapacitation of the organs of thought because they have lost the energy and
force required to perform their functions” (Huertas, 2008). He also described other conditions,
which he called monomania, lypemania, mania, and imbecility. In contrast with Pinel’s belief
that patients could only suffer from one mental illness, Esquirol noted that some patients suffered
from all of these types of mental disorders, emphasizing his belief that all patients present
different symptoms for various neurological illnesses. In one of his doctrine’s, he notes that the
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challenge of diagnosing neurological illnesses “has led some physicians to reject any distinction
and not to admit in madness any more than a single disease, presented in varied forms. I do not
share this way of seeing things, and consider the genera ... to be sufficiently different so as not to
be confused” (Huertas, 2008). He urged medical practitioners to more fully analyze their
patients, to create more individualized treatments.
Along with his progressive ideas, allowing for more thorough analysis of the patients
which would provide better patient care, he was able to further subdivide Pinel’s established
categories of psychiatric illnesses. For dementia in particular, Esquirol was able to differentiate
between three different types: acute, chronic, and senile. He specifically related senile dementia
to “old age, alterations in memory, especially the recent type, difficulty of attention and its
captious progress” (Vatanabe et al., 2020). Although this definition appears to be allencompassing, Esquiol’s identification of senile dementia sounds similar to AD. Overall,
Esquirol’s elaboration on Pinel’s work allowed for better care for patients. Esquirol continued
the reforms that were introduced by his predecessor, Pinel; both Pinel and Esquirol opened the
doors for further research to be done to better understand the mind of an individual suffering
from neurological illnesses.
Another scientist, Emil Kraepelin, seemed to follow in the footsteps of Pinel and
Esquirol. In the late 19th and early 20th century, Emil Kraepelin became a popular psychiatrist;
like Pinel and Esquirol, Kraepelin had a major impact in the field of medicine. He dedicated
most of his time in the lab, and as such, he lost his merits as a clinical physician. This did not
deter him though, as he later founded the Department of Psychiatry in Munich. He had many
important achievements in the field of psychiatry including the differentiation between ‘dementia
praecox,’ which we now refer to as schizophrenia, and ‘manic depression’ (Ebert & Bär,
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2010). He determined that ‘dementia praecox’ was a progressive neurodegenerative
disease. Even with Pinel’s and Esquirol’s asylum reforms, individuals suffering from dementia
praecox were commonly viewed as unstable and even dangerous, and ultimately did not receive
proper medical treatment. In contrast with dementia praecox, Kraepelin believed that manic
depression is “an episodic disorder, which does not lead to permanently impaired brain function”
(Ebert & Bär, 2010). Ultimately, Kraepelin’s work led to a greater understanding of treatments
and diagnoses for neurological illness. Unlike Pinel and Esquirol, Kraepelin did not show great
compassion for the patients he studied. He believed that compassion posed as an obstacle for
objective research. Instead, Kraepelin focused on the patient’s words and studied those words
incessantly, aiming to find answers, which led him to better understand neurological
illnesses. Although Kraepelin did not necessarily have a direct impact on dementia research, his
lab became renowned; famous scientist Alois Alzheimer, who actually discovered AD, was
actually a student in Kraepelin’s lab.
During the initial semesters of Alzheimer’s college career, he showed interest in anatomy
and learned how to work with microscopes. Interestingly enough, Alzheimer focused all of his
interests within the clinical realm of medicine and completely neglected the field of psychiatry
altogether (Hippius & Neundörfer, 2003). Alzheimer likely became interested in psychiatry after
being approached by a wealthy family, who needed someone to travel with their mentally ill
relative. Alzheimer allegedly traveled with this patient for five months, but neither the name or
diagnosis of the patient is known. After returning from his five month expedition, he applied for
a position at the Community Hospital for Mental and Epileptic Patients in Frankfurt. Through
this position, Alzheimer became a renowned clinician, furthering his interests in psychiatry. As
his career developed, his popularity grew and he was later invited to join Kraepelin’s lab.
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In Kraepelin’s lab, Alzheimer researched the brain of Auguste D., a woman who was
described as a 51-year-old female who had delusions, anxiety, and was disoriented and
forgetful. She additionally became extremely paranoid and believed that she expressed fears of
“being persecuted and bothered by the neighbors” (Ramirez-Bermudez, 2012). It became
apparent that she suffered from some neurological illness, at which point Alzheimer was
assigned to her case to investigate. According to Alzheimer, “she showed rapidly increasing
memory impairments; she was disoriented carrying objects to and fro in her flat and hid them.
Sometimes she felt that someone wanted to kill her and began to scream loudly” (RamirezBermudez, 2012). He also noted that she was completely unable to perform various tasks
correctly; when asked to draw the number ‘8,’ she would write her name instead. Additionally,
she was unable to recall her last name, and could only correctly provide her first name. After her
death, Alzheimer received her spinal cord and brain for study. At a conference in 1906,
Alzheimer first presented the neurofibrillary tangles and senile plagues found in Auguste D’s
brain. These findings made Alzheimer the first to link these pathological markers of disease to
Alzheimer’s disease, a term coined by Kraepelin.
Although Auguste D. was arguably Alzheimer’s most famous patient, Alzheimer also
gathered valuable evidence from Josef F. After three years of hospitalization, Alzheimer was
able to study Josef F.’s brain and determine that he had also suffered from AD. Interestingly,
this patient’s brain did not have neurofibrillary tangles, but instead showed a great accumulation
of senile plagues only. For a long time, researchers believed that Josef F.’s case was a mere
contradictory to the many other AD brains, which presented with both senile plagues and
neurofibrillary tangles. However, over time, the cases of Josef F. and Auguste D. were re-
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investigated, and it was determined that both Auguste D. and Josef F. suffered from AD, but
Auguste D. died at a much more progressive state in her disease than Josef F.
Overall, the findings from Pinel, Esquirol, Kraepelin, and Alzheimer have led to great
reforms in regards to the proper treatment for those who suffer from various neurological
illnesses. Pinel and Esquirol worked to reform asylums by literally unshackling
patients. Additionally, Pinel and Esquirol pushed for these patients to be treated with care and
respect in order to receive proper treatment. The initial reforms presented by Pinel and Esquirol
opened the doors for future healthcare providers and researchers to gain more understanding of
neurological illnesses. Kraepelin followed in the footsteps of Pinel and Esquirol by paying close
attention to the symptoms his patients presented. He worked to provide objective findings that
later allowed him to differentiate between dementia praecox and manic depression. Kraepelin
questioned the works of his predecessors to improve the field of psychiatry; Alzheimer followed
in his footsteps by understanding the pathological markers that underlie diseases, specifically
AD. Even today, there is so much unknown about AD; there is currently no cure for AD and few
treatments that effectively slow the progression of the disease. The works of these previous
researchers prove that medicine and science should be questioned until complete answers are
found.
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Neuroinflammation in Alzheimer’s Disease
AD is now the most common cause of dementia in the elderly and affects more than 4
million people in the US. AD is a progressive and deadly disease that affects cognitive function,
the ability to communicate, and the ability to carry out daily tasks. Most popularly, Alzheimer’s
pathology is defined by the presence of extracellular plaque deposits of β-amyloid peptide (Aβ)
and neurofibrillary tangles made up of protein tau. Aβ has been recognized as a protein that
disrupts synaptic function, neural connectivity, and even induces neuron death (Murphy &
LeVine, 2010).
Inflammation in the brain is one of the hallmarks of AD; at first, this inflammatory
response acts to eliminate cell injury and dead cells and tissues. However, over time, this
inflammation becomes chronic, destroying the surrounding tissues, leading to severe tissue
deterioration. This inflammatory response is driven by microglia, astrocytes, and neurons.
Specifically, regarding inflammation in AD, β-amyloid (Aβ) plaques and neurofibrillary tangles
activate inflammatory cells, such as astrocytes and microglia. Responses from cytokines and
chemokines tend to be altered due to this inflammation, and altogether further propel this
neuroinflammatory response. Inflammation initially occurs as a sort of protective response
against stress, injury, or infection. Unfortunately, this continued inflammatory response
contributes to the progression of AD. Microglia has been shown to play an important role in
AD. Microglia has both protective and neurotoxic effects in the brain. Activated microglia
release proinflammatory mediators. Aβ, which is a hallmark of AD, can attract and activate
microglia (Rubio-Perez & Morillas-Ruiz, 2012). Activated microglia can release toxic factors,
which can lead to neuroinflammation and may trigger the progression of AD. Additionally,
astrocytes are attracted to Aβ deposits in AD suggesting that these lesions may in part induce
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astrocyte recruitment. Astrocytes play a role in Aβ clearance and degradation; however, they
tend to release proinflammatory molecules are thought to accelerate the progression of AD.
Neurons also contribute to this neuroinflammation; they produce several chemokines and
cytokines, which act to result in proinflammatory cytokine production in microglia. These proinflammatory mediators may trigger further neuroinflammation and lead to further neuronal
damage in AD pathology (Rubio-Perez & Morillas-Ruiz, 2012).
The identification of Aβ in the autopsied brains of individuals with AD led to the amyloid
cascade hypothesis, which essentially asserts that Aβ plaque deposits result in neuronal death,
leading to cognitive decline. This hypothesis has since been supported due to the finding that
AD inducing mutations in amyloid precursor protein (APP), presenilin 1 (PS1), and presenilin 2
(PS2) genes, all of which increase Aβ production. The cleavage of APP, via the sequential
cleavage by β- and γ-secretase generates Aβ fragments. Although all of the exact functions of
APP remain elusive, overexpression of APP is known to maintain neural integrity.
Microglia likely play a role in the inflammatory response in patients with AD; in a
healthy brain, microglia are inactive. When microglia sense damaged tissue, this leads to
microglial activation. Different phenotypes of microglia have different functions: M1 has a proinflammatory function, while M2 has an anti-inflammatory function. In patients with AD, it has
been proposed that pro-inflammatory microglia are activated in the presence of Aβ, resulting in
phagocytosis of Aβ. After an extended period of time, microglia are no longer able to process
Aβ, leading to accumulation of Aβ; this could be due to a malfunctioning TREM2 gene.
TREM2 essentially instructs microglia to clear debris or plaque build-up around a neuron. When
this gene does not function properly, and the microglia sense damage, they accumulate around
the neuron, but do not complete their job by clearing away plaque, potentially causing the Aβ
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accumulation in individuals with AD (What Happens to the Brain in Alzheimer’s Disease?,
2017). Due to the inability to process Aβ, pro-inflammatory cytokines are released, exacerbating
neuroinflammation and contributing to neurodegeneration, and increased activation of microglia.
Microglia represent the first line of defense against invading pathogens or other brain tissue
injury. These cells aim to clear debris from the damaged area. Microglia may be associated with
amyloid plaque; disruption of the APP gene delays microglial activation. In most ways, the role
of microglia has been found to be beneficial. Studies have indicated that activated microglia can
reduce Aβ accumulation by increasing phagocytosis. Therefore, microglia may be utilized in a
future approach for human Aβ immunization. Chemokines, which are expressed and secreted by
neurons, act as regulators of microglial migration and recruitment of astrocytes, likely play a role
in inflammatory responses in the brain. Various chemokines have shown to be upregulated in
AD, generating an upregulated deposition of microglia and astrocytes to damaged areas in the
brain, potentially leading to further inflammation, which of course could lead to AD
development (Kinney et al., 2018).
Tumor necrosis factor (TNF) is a pro-inflammatory cytokine that is commonly
upregulated in the brains of individuals with AD. TNF acts to upregulate other proinflammatory cytokines such as IL-1 and IL-6 both of which are also commonly upregulated in
individuals with AD (Su et al., 2018). Interestingly, one study showed that when TNF knockout
mice were injected with bacteria, there was no protective response, and the mice developed a
severe and inflammatory reaction, resulting in death. Thus, the study indicates the initial
inflammatory response by TNF is protective; however, in individuals with AD, this response
becomes cyclical and eventually causes more harm, damaging brain tissue and ultimately
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resulting in cognitive decline. TNF also increases the production of Aβ, a hallmark of AD (Su et
al., 2018).
Astrocytes additionally play an important role in Aβ clearance, by supporting neurons. In
some conditions, however, overactivity of astrocytic β-secretase results in increased generation
of Aβ in chronic stress, suggesting that astrocytes play a role in the inflammatory response in
AD. Additionally, recent studies have shown that neurons play a role in neuroinflammation.
Evidently, neurons generate inflammatory molecules, further contributing to the inflammatory
response in AD pathology (Kinney et al., 2018). Additionally, neurons produce and secrete
various chemokines and cytokines, both of which are upregulated in individuals with AD.
Cytokines, which are secreted by immune cells as well as neurons, play a role in
inflammatory responses. Most cytokines are produced by neurons or glia; given that numbers of
glia and neurons are increased in AD brains, cytokines likely play an important role in
neuroinflammation responses. Cytokines are referred to as either proinflammatory or antiinflammatory. Inflammatory cytokines are secreted by microglia and astrocytes and contribute
to neuronal death. Inhibitory cytokines can suppress proinflammatory cytokine production,
which is critical to the concept of balance among both types of cytokines. Dysregulation of this
balance can lead to cytokine production which can induce cytotoxicity, which is prevalent in AD
pathology.
Recent studies have indicated that Triggering Receptor Expressed on Myeloid Cells- 2
(TREM2) may additionally play a role in AD pathology. There are three important roles that
TREM2 may play. In AD pathology: 1) regulation of phagocytic and autophagic processes; 2)
myeloid cell survival and proliferation; and 3) regulation of inflammation. Myeloid cells have
the ability to mature into red blood cells or various types of white blood cells (Raymaakers,
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2020). Studies have shown that myeloid activation patterns, which at some point rely on
TREM2, convert to a neurodegenerative pattern, altering phagocytosis and lipid metabolism.
Lastly, growth factors, which are proteins that support the survival of cells of the central
and peripheral system play a role in the development of the brain, regulating the growth of
different cells in the brain. Nerve growth factor (NGF) is commonly unregulated in patients with
AD, indicating that NGF plays a specific role in AD development. Studies have indicated that
NGF accumulates in neurological disease, emphasizing the idea that NGF might play a role in
inflammatory responses in the brain of individuals with AD (Kinney et al., 2018).
Just as the amyloid cascade hypothesis accounts the accumulation of Aβ plaque deposits,
the tau hypothesis accounts for the hyperphosphorylation of tau. Like amyloid plaques,
neurofibrillary tangles are a hallmark of AD. Tau is a microtubule-associated protein (MAP)
which helps to stabilize neuronal microtubules (Mandelkow & Mandelkow, 1998). Microtubules
in a neuron are generally found in the axon and help to provide structure to the cytoskeleton of
the cell as well as assist in transporting substances to different parts of the cell. Tau can be
phosphorylated at many sites, some of which are responsible for microtubule-binding
(Mandelkow & Mandelkow, 1998). Normally, tau is soluble and unfolded, but when tau is
mutated, tau can become hyperphosphorylated, which ultimately leads to death by
apoptosis. Additionally, hyperphosphorylated tau shows improper microtubule binding, leading
to a breakdown of the cytoskeleton of the cell as well as an inability to transport substances to
different parts of the cell. Tau aggregates, called ‘paired helical filaments’ (PHF) form as a
result, which then turn into insoluble neurofibrillary tangles. These tangles accumulate over
time, blocking synaptic communication between neurons (What Happens to the Brain in
Alzheimer’s Disease?, 2017). The inability of neurons to communicate to one another as well as
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the inability for microtubules to transport essential nutrients causes the neuron to be unable to
create and process various proteins, ultimately leading to cell death. Tau tends to accumulate
starting in the entorhinal cortex, an area involving smell, indicating one reason why many
individuals with AD tend to lose their sense of smell first. Tau aggregates then tend to
accumulate in the temporal and frontal parts of the brain, resulting in affected speech and
executive functions (Yang et al., 2005). Additionally, research has shown that the inflammatory
processes involved in the AD brain can induce tau hyperphosphorylation via the MAPK
pathway. This pathway is responsible for directing responses from different stimuli, including
proinflammatory cytokines. Thus, the inflammatory response that induces hyperphosphorylation
of tau then causes an upregulation of proinflammatory cytokines, encouraging a proinflammatory
cycle (Zilka et al., 2012).
Researcher Yang emphasizes the concept that it appears that once neuroinflammation
begins, this cycle of neuroinflammation continues, causing AD to progress as a result of the
accumulation of amyloid β-amyloid and neurofibrillary tangles. Yang points out that “immune
cells are activated and produce a variety of inflammatory mediators such as cytokines and
chemokines” (Yang, 2019). Chemokines and cytokines are known to play a role in the
progression of AD through various inflammatory processes. Past studies have even indicated
that “elevated cytokine levels are significantly correlated with microglial activation and have
effects on Aβ generation, neurodegeneration, and cognition” (Yang, 2019), which is one reason
why individuals who suffer from AD show memory and other cognitive declines. Additionally,
it is evident that microglia, astrocytes, and neurons seem to begin and even perpetuate this
neuroinflammatory cycle, causing AD to progress, and cognitive function to decline. It is
important to understand that the production of one type of molecule does not explain the
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neuroinflammatory processes that occur in the brains of AD individuals; this neuroinflammation
is a perpetual cycle induced by a combination of many factors, which initially cause the
accumulation of Aβ plaques and neurofibrillary tangles. Both of these entities essentially
contribute to the overall neuroinflammation in AD individuals.
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Modern Forms of Treatment
Unfortunately, there is currently no cure for AD; however, researchers and healthcare
providers work hard to find the best approaches to delay the progression or onset of
AD. Currently, there is no treatment option that can help to delay the progression of the disease,
once the disease has progressed to a certain extent. Few medications are currently marketed to
individuals diagnosed with AD. Thus, as of now, it is vital that healthcare practitioners advise
their patients to make healthy lifestyle choices in efforts to prevent the onset of the disease.
Because many believe that a proinflammatory response in the brain is one mechanism
through which an individual can suffer from resulting AD, some treatment options directly attack
these proinflammatory processes in the brain. One such treatment option is the use of nonsteroidal anti-inflammatory drugs (NSAIDs). NSAIDs are a group of drugs that aim to decrease
inflammation and reduce fevers by blocking cyclooxygenase (COX), an enzyme that produces
prostaglandins, lipids that are made at sites of tissue damage or infection. By limiting the
amount of prostaglandins, individuals should see pain relief and reductions in fevers. Although
NSAIDs are most commonly used to treat pain or fevers, interestingly, studies have shown that
individuals can reduce their likelihood of developing AD as a result of taking NSAIDs (Ozben &
Ozben, 2019). Some patient studies have indicated that NSAIDs can reduce the incidence of AD
by 30-80%; this wide range indicates the more research needs to be conducted to understand the
usefulness of NSAIDs in AD prevention.
Researchers have also utilized animals to understand the role NSAIDs potentially play in
AD prevention. One animal study used a Tg2576 line of APP-transgenic mice; this particular
mouse model causes the mice to show characteristic symptoms of AD as well as the
inflammatory processes known to induce AD. Through the course of this study, mice were given

27

a substantial dose of ibuprofen (62.5 mg kg day ), a common NSAID used as a painkiller. Over
-1

-1

the course of a six-month trial, the mice showed a significant reduction in “amyloid plaque
pathology and Aβ levels, reduced microglial activation and reactive astrocyte numbers, and
reduced levels of the pro-inflammatory cytokine IL-1β” (Weggen et al., 2007). Subsequent
studies utilizing this particular mouse model have shown similar results.
NSAIDs are believed to interfere with pro-inflammatory cytokines such as IL-1 and TNF-α, both
of which are upregulated in individuals with AD. Both of these cytokines upregulate
COX. An enhanced expression can upregulate neurons, astrocytes, and microglia, which over
time can lead to increased neuronal loss. Interestingly, blocking COX can also induce neuronal
loss. Although the use of NSAIDs could potentially prevent the onset of AD, the mechanism by
which this occurs is not fully understood. Additionally, COX is not believed to be upregulated in
individuals with AD and “neuronal COX expression has been found to be unchanged in the
Tg2576 mouse model of AD” (Weggen et al., 2007). The usefulness of NSAIDs in treating and
preventing AD has been disputed, and healthcare practitioners are currently not advised to
prescribe NSAIDs for the sole purpose of treating or preventing AD.
Although this finding has been disputed, “the incidence of AD was found lower in
patients with rheumatoid arthritis with long-term NSAIDs medication” (Ozben & Ozben, 2019).
Thus, NSAIDs prove to be a promising therapeutic option or a potential preventative treatment
for individuals who are at a higher risk of developing AD. Another study tried to analyze the
usefulness of the NSAIDS naproxen and celecoxib in preventing AD; unfortunately, this study
showed that the use of these particular NSAIDs did not seem to prevent the onset of AD. In fact,
this particular study had to be halted, due to the increased incidence of cardiac disease in patients
specifically treated with naproxen (Ozben & Ozben, 2019). Although NSAIDs show potential in
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treating or preventing the onset of AD, results have been disputed. Additionally, with the
associated side effects and risks associated with long-term NSAID use, there is no official
directive for healthcare providers to prescribe NSAIDs with the sole purpose of preventing AD.
Although NSAIDs have the ability to reduce the inflammatory processes and clear Aβ
plaques in the brain, they are currently not a suggested therapy due to the various side effects of
long-term usage. Currently there is a great need for AD drug research, because there are few
effective therapies available. The two classes of drugs used to treat AD are called cholinesterase
inhibitors as well as an N-methyl D-aspartate (NMDA) antagonist. These drugs are effective in
reducing the symptoms of AD, which can provide relief to patients and families.
There are three different drugs classified as cholinesterase inhibitors that are approved
treatment options for individuals with AD, which include donepezil, galantamine, and
rivastigmine. Currently, donepezil is used to treat all stages of the disease, galantamine is used
to treat mild to moderate forms of AD, and rivastigmine is also used to treat mild to moderate
forms of AD (Alzheimer’s Association, 2021). All three drugs come with various side effects,
including nausea, vomiting, and loss of appetite, but overall these medications are tolerated
well. Cholinesterase inhibitors are used to treat cognitive symptoms, such as memory loss,
confusion, and problems with thinking and reasoning (Alzheimer’s Association,
2021). Cholinesterase inhibitors are “a group of drugs that block the normal breakdown of
acetylcholine (ACh) into acetate and choline and thereby increase both the levels and duration of
actions of acetylcholine found in the central and peripheral nervous system” (Singh & Sadiq,
2020). Acetylcholine plays a major role in memory and overall cognition, thus the increased
acetylcholine as a result of consuming a cholinesterase inhibitor could effectively treat cognitive
symptoms. Cholinesterase inhibitors also have the added benefit of improving muscle activation,
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contraction, and strength due to the increased acetylcholine at neuromuscular junctions (Singh &
Sadiq, 2020). Additionally, cholinesterase inhibitors are effective at delaying the progression of
the disease, which can provide overall relief to patients and families.
Additionally, a medication called memantine, an NMDA receptor, is also a verified
treatment option for individuals with AD. This medication acts to “Block the toxic effects
associated with excess glutamate and regulates glutamate activation” (How is Alzheimer’s
Disease Treated?, 2018). More specifically, “The principal mechanism of action of memantine
is believed to be the blockade of current flow through channels of N-methyl-d-aspartate
(NMDA) receptors--a glutamate receptor subfamily broadly involved in brain function” (Johnson
& Kotermanski, 2006). This medication is approved to treat moderate to severe forms of AD
and has even been shown to have neuroprotective effects; memantine has been shown to improve
mental function and the ability to perform daily activities for some people, allowing individuals
with AD to retain their independence, something that is consistently lost through the progression
of the disease.
Ultimately, these approved treatments are great options for individuals suffering from
AD. They can relieve symptoms and ideally allow an individual to retain their independence for
a longer period of time. Losing an individual’s independence and having to rely on others for
activities of daily life can generate frustration and a loss of hope in many patients. Thus, the use
of these medications could make a huge impact on an individual’s overall well-being.
Cholinesterase inhibitors and NMDA receptors, both of which are currently marketed as AD
medications, have specific methods of action, by reducing the breakdown of acetylcholine and
regulating glutamate activity, respectively. Although there are few treatments available to
patients, these treatments are effective. Ideally, future research will find therapies that are
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neuroprotective and can alter the course of the disease, relieving patients and families of the fear
that accompanies an AD diagnosis.
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Failures of Treatments
Given that AD is characterized by Aβ plaques and tau proteins, researchers initially
hypothesized that removal of the buildup of these proteins could cure AD. Unfortunately, after
several failed drug trials in which patients did not have improved memory, agitation, or anxiety,
researchers looked to different mechanisms that played a role in the development of AD.
Interestingly enough, survivors of the 1918 flu pandemic were at a higher risk of developing AD
(Myrskylä et al., 2013). Thus, researchers began to wonder if antimicrobials, which help the
immune system fight disease, play a role in AD development and progression. Eventually,
researchers were able to determine that microglia and astrocytes, which play a role in brain
function, play a unique role in the immune system as well and may promote AD development.
Astrocytes and microglia initially cause neuroinflammation in the brain when aiming to fight off
disease or invading pathogens; however, this continued neuroinflammation is harmful and can
lead to AD. Although the exact process remains unclear, research has concluded that
environmental pollutants and genetics play a large role in the risk associated with AD. For
example, gum disease, herpes virus, and gene APOE4 implicate a greater risk of developing AD
as a result of initiating the inflammatory processes in the brain. In the coming years, antiinflammatory drugs will be continuously developed in efforts to at least halt the progression of
AD (Weintraub, 2019).
It is important to understand various contributors to the pathology of AD, to allow
researchers to find effective targets for therapies. Researchers have developed few effective
therapies that help to combat the symptoms of AD. Currently, the medications marketed for AD
allow patients to retain their independence for a longer amount of time, but there are few drugs
available to treat AD; thus, future research is necessary to find new drugs, allowing individuals
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to find a treatment option that is best for them. Additionally, most of the drugs on the market
delay the onset or progression of symptoms, but fail to change the outcome in a patient’s
life. Ultimately, the disease will kill the patient. The strides in AD research have made major
breakthroughs allowing for better understanding of the complex mechanisms involved in the
onset of the disease; however, still, no drug has the power to reverse the path of the
disease. Researchers and healthcare providers are racing for a cure, hoping to heal their patients,
better the lives of families, and ease the economic burden imposed by AD.
Along with the motivation to allow for increased quality of life in patients with AD, the
large economic burden imposed by AD is a great incentive for researchers to find a
cure. According to the President and CEO of the Alzheimer’s Association, Harry Johns, “Caring
for people with Alzheimer’s will cost all payers - Medicare, Medicaid, individuals, private
insurance and HMOs -- $20 trillion over the next 40 years, enough to pay off the national debt
and still send a $10,000 check to every man, woman and child in America” (Johns, 2013). This
is a staggering statistic implying that the impending cost acquired through the care of AD
patients not only affects patients and families, but also places a burden on the economy; major
breakthroughs need to be made immediately in the realm of AD research. Additionally, the
World Dementia Envoy, Dennis Gillings, explains that ‘Dementia is a ticking bomb costing the
global economy £350 billion and yet progress with research is achingly slow (Burke,
2014). Gillings and Johns would likely agree that there is a great need for AD research,
especially to dampen the economic burden placed on families, patients, and all other payers.
Aside from the economic burden of AD, families are strongly affected by an AD
diagnosis. On the Alzheimer Society website, family members share their stories of loved ones
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affected by the deadly disease under the hashtag #StillHere. Rachel Smith, a 26-year-old,
explains that her father was recently diagnosed. She writes that “I hope that one day Dad will be
able to walk me down the aisle and hold my future children in his arms, but I fear that he may
not be able to when the time comes” (#StillHere - five personal stories, 2021). Rachel goes on to
explain that her father’s diagnosis has been devastating to deal with as a 26-year-old. She
describes the dramatic role reversal, requiring her to take care of her father, rather than her father
taking care of her. Another woman, Samantha, describes her mother’s recent AD
diagnosis. Like Rachel, Samantha is a young 26-year-old; she struggles to find time to finish
school and find a career while acting as the primary caregiver to her mother. Samantha explains
that the most devastating aspect of the disease is the concept that her mother may one day forget
her. Samantha writes “I still have my mom physically, but I’m losing more and more of her. My
mom has accepted having dementia and knows that something is wrong, that her brain isn’t
working ‘right’, but she doesn’t like to use the word ‘Alzheimer’s’. She’s depressed and cries a
lot, saying she hates this disease and that she wishes it never happened to her. On the worst day
it’s only our toy poodle, Lucy, who can bring a smile to her face” (Meet Samantha and Shawn,
2020). It is clear that this disease takes a toll on families. The devastating news of an AD
diagnosis causes family members to feel like they have already lost a family member, given the
inevitable outcome of the disease.
Patients who are diagnosed with AD additionally suffer not only from the symptoms of
the disease, but also from the grief of knowing and understanding the progression of the
disease. The Alzheimer’s Association website posted “Alzheimer’s: A Real Love Story…”
which describes a beautiful story between married couple Mark and Julia Balson. Married for 47
years, Mike and Julia enjoyed an adventurous life together, full of traveling, time spent with their
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kids as well as each other. Eventually, Mike received the devastating news of an AD diagnosis,
completely turning his world upside down. In his youth, Mike was the picture of health; he had
even played professional soccer in the U.K. for more than a decade. Thus, the couple never
predicted an AD diagnosis. Both Julia and Mike discuss that symptoms had been apparent for
months, but the couple often excused Mike’s forgetfulness as purely mental
fogginess. Eventually, Mike sought help from a healthcare practitioner who was able to provide
Mike with a diagnosis. Although the family found peace in knowing and understanding Mike’s
symptoms, they struggled to deal with the prognosis of AD. They acknowledge that both of
them have “off” days, but that ultimately this hardship has made their relationship stronger;
however, their relationship does not look the same. Mike describes one of the most upsetting
aspects of the disease is that he is unable to take care of his wife like he used to. The role
reversal has shifted the dynamic of their relationship, and although Mike struggles with the
inability to provide and properly care for his wife as he sees fit, he acknowledges that his wife is
the only person he would ever want taking care of him. He believes the strength of their
relationship will allow them to face this disease head-on, together.
Clearly, the devastation that families and patients feel as a result of an AD diagnosis is
insurmountable; patients fear of forgetting their loved ones, and family members fear of being
forgotten. Although great strides have been made in the realm of AD research, the need for a
cure is apparent now more than ever. Because the baby boomer generation is turning 65, and
because aging is the biggest risk fact in the disease, more and more people will inevitably be
diagnosed with AD than ever before. Additionally, the economic burden of AD is extreme; thus,
there is a great need for curative AD research. Currently, there are several clinical trials
underway. In the past, research has targeted a range of different mechanisms involved in the
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onset of AD, including monoclonal antibodies, Gamma secretase inhibitors, and neurochemical
enhancers (Mehta et al., 2017). Unfortunately, these trials were unsuccessful, causing
researchers to look at different AD causing pathways. It is imperative to understand and analyze
different failed treatments in order to move forward with AD research.
Although many of the mechanisms that induce AD are widely understood, which in turn
allowed for the generation of the amyloid cascade hypothesis as well as the tau phosphorylation
hypothesis, there is still no cure for this progressive and deadly disease. Many pharmaceutical
companies, hospitals, and private organizations have been on a wild goose chase, searching for a
cure for AD. Unfortunately, approximately 99% of of AD drugs fail, according to a study
conducted by the Cleveland Clinic Lou Ruvo Center for Brain Health (Drugs Discovery Trends
Editor, 2019). This consistent failure in treatments likely pertains to the fact that, although many
of the mechanisms contributing to AD are well understood, the efficacy of one drug likely will
not have a major impact on the progression of the disease, because of the complexity of the
various mechanisms that contribute to AD onset. Over the course of decades, companies have
continued to try to find a cure or better forms of AD treatment, with little to no luck. For
example, between 2002 and 2012, 244 compounds were studied in 413 clinical trials; however,
only one drug was approved. Because of the complexity of the disease, it is extremely
challenging and likely discouraging for the researchers who long to find a cure or different
treatment. Along with the challenges researchers face as they strive to find a cure, unfortunately,
AD research is widely underfunded in comparison to the challenges imposed by the disease
(Drugs Discovery Trends Editor, 2019). Thus, more funding is essential for future research.
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Along with increased AD research funding, it is important that researchers understood
previously tested and failed treatments in order to further understand the complex mechanisms
involved in the disease. Recently, Eli Lilly Pharmaceuticals developed a drug called
solanezumab. This drug was created to target and remove or prevent the accumulation of
amyloid, which in turn, they hoped would prevent AD progression (Belluck, 2016). Phase 1 and
2 clinical trials of solanezumab showed great results; the drug was tolerated well in healthy
volunteers and in patients with mild to moderate AD (Almeida, 2019). Thus, researchers were
confident in the drug’s ability until Phase 3 of clinical trials. During this clinical trial, the
researchers were hoping to see that the drug helped to slow cognitive decline in patients
suffering from mild to moderate AD. They were able to determine that individuals suffering
from AD showed less worsening in cognition versus the placebo group; however, these results
were not statistically significant. Additionally, the effects of solanezumab showed “no evidence
of slowing of cognitive or functional decline...in those subjects who had moderate AD at study
commencement” (Siemers et al., 2016). Ultimately, the researchers were unable to provide an
absolute conclusion in regards to the efficacy of solanezumab in patients with mild to moderate
AD, which called for termination of the clinical trials. However, the drug is currently being
tested in clinical trials for individuals who are at risk of developing AD (Belluck, 2016). The
President and Chief Executive of Eli Lilly, Dave Ricks, admits that the failure of solanezumab
was heartbreaking, because the results indicated that the drug would not be effective in altering
the progression of the disease. However, the study was able to provide insight in regards to the
complexity of the disease. Dr. Lon Schneider, director of the California Alzheimer’s Disease
Center at the University of Southern California recognizes that “as the brain is failing or dying, it
is dying on all levels” (Belluck, 2016) implying that the efficacy of one drug potentially depends
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on the drug’s ability to alter multiple different mechanisms in the brain. Future clinical trials for
solanezumab will ideally show that the drug is able to clear or prevent amyloid accumulation in
individuals that have not received an official AD diagnosis, preventing the onset of the disease.
In addition to Eli Lilly’s recent trials for solanezumab, Roche Diagnostics produced a
drug called gantenerumab. Like solanezumab, gantenerumab was created to “connect to
aggregated forms of beta-amyloid and remove beta-amyloid plaques, a pathological hallmark of
AD that is believed to cause brain cell death” (Roche's gantenerumab fails to meet primary
endpoint in Alzheimer's Disease trial, 2020). Researchers predicted that the removal of Aβ
plaques would prevent the progression of the disease as well as restore various cognitive deficits
that result from AD. Unfortunately, the study failed to meet its primary endpoint, indicating that
the drug was unable to slow the rate of cognitive decline in individuals with autosomal dominant
AD. The drug is now being tested in other clinical trials, with hopes that gantenerumab will
have the ability to protect individuals with a form of AD that is not directly caused by a
gene. Ideally, this drug will be able to reverse the inevitable deadly progression of AD, allowing
for relief amongst patients and families.
Thus far, researchers and pharmaceutical companies have been unable to develop an effective
drug that combats the accumulation of Aβ plaque in AD brains. Other drugs have been
developed to treat different mechanisms in the AD brain. For example, a drug called
idalopiridine was developed jointly by Lundbeck and Otsuka Pharmaceuticals (Kegel,
2018). This drug was developed as “a neurochemical enhancer that antagonizes 5-HT6
receptors. Inhibiting 5HT6 enhances acetylcholine release in the brain and is therefore procholinergic” (Mehta et al., 2017). Therefore, the drug was created to relieve symptoms of AD,
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rather than change the direction of the disease’s course (Kegel, 2018). Phase 2 trials were able to
show that the drug was effective in improving cognition; however, phase 3 trials did not show
these same results. Although this difference in results may seem contradictory, there was one
major difference between phase 2 and phase 3 trials: the dosage. In phase 2 trials, the
participants received a 90 mg dose of idalopiridine, three times daily. The U.S. Food and Drug
Administration suggested in the phase 3 trial, that the dosage should be lowered and additionally
that participants should only receive the medication once daily. The U.S. Food and Drug
Administration determined that the “side effects of the treatment were relatively common in the
Phase 2 study. In addition, other research showed that idalopiridine bound to more than 80
percent of its target receptors at much lower doses, suggesting the high dose was unnecessary”
(Kegel, 2018). Although it was determined that a high dosage of idalopiridine was unnecessary,
the phase 3 trials provided different results than the phase 2 trials; the phase 3 trials showed no
improvement in cognition. It has not been determined why these differences in results were
produced; however, given the lowering of the dosage as well as the lessening of the distribution
of the drug to participants from three times daily to once daily, these differences could have
impacted the efficacy of the drug for unknown reasons. Although the phase 3 trials provided
disappointing results, the data was shared with the Critical Path of Alzheimer’s Disease (CPAD)
consortium database, allowing for CPAD to “develop a model of disease progression across the
entire spectrum of Alzheimer’s from its earliest to late stages” (Pataia, 2020). Thus, although the
drug ultimately failed to improve cognition in patients with mild to moderate AD, the data
collected will further contribute to AD research and allow for a more thorough understanding of
the disease progression. Dr. Dave A. Bennett of Rush University Hospital believes that with the
data collected from the idalopiridine trials, “It is just a matter of time before that knowledge is
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translated into effective strategies for the treatment and prevention of Alzheimer disease
dementia” (Kegel, 2018).
These failed treatments that have been discussed thus far have been unable to improve cognition
in patients and have additionally failed to reverse the progression of the disease. Other drugs
have been developed to target different mechanisms of the disease, and in 2009, a drug called
avagecestat was developed “for the selective inhibition of β-amyloid synthesis” by inhibiting γsecretase (Avagacestat ineffective for Alzheimer's disease, n.d.). Phase 1 trials indicated that the
drug was effective in decreasing the amount of Aβ plaque build-up in the brain in AD
participants, furthering researchers’ belief in the drug’s promising results. The drug proceeded
to phase 2 trials, where, unfortunately, the “Researchers observed increases in nonmelonoma
skin cancer” (Avagacestat ineffective for Alzheimer's disease, n.d.), indicating that the drug is
unsafe and should not be administered to patients suffering from mild to moderate forms of
AD. Gastrointestinal side effects also occurred, including diarrhea, nausea, and vomiting
(Avagacestat, 2021). Along with the low tolerance of avagecestat among participants, the drug
showed no significant effectiveness in comparison to placebo groups; patients in the treated and
placebo group showed disease progression at similar rates, as was indicated by assessment of
participants’ brain imaging and fluid biomarkers, as well as cognition (Avagacestat,
2021). These were devastating findings given that participants suffered tremendously as a result
of receiving and taking avagecestat. Additionally, one study indicated that, rather than lowering
the amount of Aβ plaque in the AD brain, the consumption of the drug increased Aβ production
at low doses, and therefore contributed to increased cognitive decline (Toyn, 2015). Researcher
Jeremy Toyn argues that “The known limitations make new AD trials with [gamma secretase
inhibitors] very unlikely, so future γ-secretase-targeted compounds would have to display a
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radically different mechanism” (Toyn, 2015). Thus, the future of the effectiveness of gamma
secretase inhibitors as a treatment option for individuals for AD will likely be ineffective, unless,
as Toyn states, a gamma secretase inhibitor is able to target and affect different mechanisms in
the brains of AD patients.
Although these different drug trial failures may cause the search for a cure to seem
hopeless, even these failed drug trials have provided insurmountable evidence in regards to the
different mechanisms involved in AD. For example, the data collected from the clinical trials for
the neurochemical enhancer, idalopiridine, provided information regarding the progression of
mild to moderate forms of AD, allowing for an exact model of various mechanisms to be
produced. This information will allow for future and more accurate research to be conducted for
AD. Evidently, it has become clear that the drugs that have been used in various trials only aim
to relieve one mechanism involved in AD, when in reality, many mechanisms are involved in
AD progression. Ultimately, I predict that the efficacy of an AD drug will depend on the drug’s
ability to alter multiple different mechanisms as well as relieve the symptoms that result from
those various mechanisms. Additionally, research has shown that certain drugs will likely never
be a feasible AD treatment, which is still a step in the right direction. For example,
unfortunately, the gamma secretase inhibitor, avagecestat, likely caused a further progression of
cognitive decline as well as caused nonmelanoma skin cancer in many participants. Researchers
now realize that gamma secretase inhibitors are likely not a feasible treatment option for
individuals suffering from mild to moderate forms of AD. Lastly, solanezumab, a drug created
to remove or prevent the accumulation of Aβ plaques, had promising data in Phase 1 and Phase 2
trials, but the drug was ultimately unable to slow the progression as well as reverse the course of
the disease. Researchers are taking steps in the right direction and learning more and more each

41

day about the complexity behind the mechanisms involved in AD. These failed drug trials
presented beneficial data that will allow researchers to target different, and hopefully, multiple
mechanisms involved in AD progression. Without these failed treatment options, researchers
would not have as much insight to the progression of disease; the results from these drug trials,
although devastating to patients and families, provide insight and allow for better research to be
conducted. Hopefully, an effective drug will be introduced soon, easing the burden of patients
and their families.
Additionally, researchers have tried to understand why exactly these drugs are not
producing their desired results by easing symptoms and changing the direction of the
disease. According to Mehta et al., current research has been focused on reversing the course of
the disease, whereas researchers need to instead focus on symptom relief. Further, Mehta et al.
argues that “When long-term trials were done to try to detect disease modifying drug effects, the
risk of losing subjects increased and there were other compromises to the integrity of the trial”
(Mehta et al., 2017). Because AD is a progressive and deadly disease, over the course of a longterm trial, participants may die or otherwise be unable to participate as a result of failing
health. Thus, for more accurate data acquisition, more resources, including a higher number of
participants as well as research sites, is required. These cost a lot of time and money, making
these needs challenging to attain. Additionally, Mehta et al. argues that the Alzheimer’s disease
Assessment Scale – Cognitive (ADAS-Cog) is not an accurate measure of cognition among
participants within clinical trial studies, because this scale is not standardized. A more accurate
measurement tool is required to determine a better representation of the results of these clinical
trials. Mehta et al. argues that “Although the ADAS-Cog is the gold standard in clinical
dementia trials, the administration procedures, work sheets, and scoring procedures of the
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ADAS-Cog were not clearly defined in the original article about the test” (Mehta et al., 2017)
making this measurement inaccurate across different clinical trials. Lastly, Mehta et al. argues
that these treatment options may be given to individuals for whom it may be too late, which
could indicate why so many different treatment options have failed in the past. Therefore,
treatments that can altogether prevent the development of AD would likely be key to AD
therapy. Additionally, it may also be beneficial to try to find treatments that can relieve
symptoms, rather than reverse the disease, which could provide comfort to patients and families.
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Preventative Medicine
Currently, there is no cure for AD; thus, it is important to understand the risk factors
involved with the development of AD to aim to prevent its onset. Due to medical advancements,
life expectancy has increased, causing age to be the greatest known risk factor associated with
AD (Cass, 2017). Ultimately, due to the aging population and the lack of a cure, it is important
to try prevent AD onset, especially in at-risk individuals.
The benefits of exercise have been long understood; different forms of exercise can build
endurance, strengthen muscles, improve mood, and can even combat certain medical conditions
such as depression, anxiety, and arthritis (Mayo Clinic, 2019). Additionally, exercise has been
shown to improve cognition, which is heavily impaired in patients with AD. Thus, exercise may
be a beneficial method for delaying the onset of AD. The Canadian Study of Health and Aging
showed that when controlling for age, sex, and education, individuals who consistently exercise
were less likely to show cognitive decline in comparison to sedentary individuals (Stranahan,
2012). It is currently understood that the inflammatory response in AD brains further promotes
AD development by promoting microglia to areas of inflammation, furthering this inflammatory
response, resulting in cognitive decline. Researchers have discovered that different phenotypes
of microglia play different roles by either promoting inflammatory or anti-inflammatory
responses. M1 phenotype tends to drive a pro-inflammatory response in contrast with M2
phenotype. The environment in the AD brain tends to promote an inflammatory response,
therefore encouraging the production of M1 phenotype. Interestingly, exercise has been shown
to promote the conversion from M1 to M2, therefore driving an anti-inflammatory response in
AD brains, specifically in the hippocampus. The hippocampus faces great damage due to proinflammatory microglia; thus, the conversion from M1 to M2 microglia has ultimately been
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shown to improve cognitive function. Additionally, recent research has shown that “the infusion
of plasma containing exercise-induced factors obtained from mice that performed voluntary
physical exercise during 28 days to sedentary mice resulted in a downregulation of hippocampal
neuroinflammatory processes” (Valenzuela et al., 2020), furthering the implication of the
beneficial role of exercise in preventing AD.
Additionally, animal research has played an important role in identifying the importance
of exercise in preventing the onset of AD, and more specifically, of mitigating the proinflammatory response driven by microglia, among other cellular components in the brain. One
study utilized the Tg2576 AD mouse model, which results in the overexpression of APP and the
resulting accumulation of AB deposits and amyloid plaques. These mice were placed into
control/sedentary groups versus experimental/exercise groups. The control group performed no
exercise, while the experimental group ran consistently on a mouse wheel for approximately 1618 months. The control group showed increased levels of interleukin-1β and TNF-α, both of
which play a role in the pro-inflammatory response in the brains of individuals with AD.
Consistent running in mice also showed increased hippocampal dependent learning, furthering
the importance of exercise in efforts to prevent AD.
Interestingly, the results of this specific study were mixed; exercise did not show
reductions in AB deposits or APP levels, but still showed improvements in cognition within a
radial arm task as well as a water maze task. Researchers have thus theorized that the
improvement in cognition is a result of the modulated expression of chemokines, rather than the
decreased levels of AB deposits and APP. These findings have pointed researchers in new
directions for treatments, suggesting that modulation of inflammatory chemokines may be a
potential therapeutic target (Stranahan et al., 2012).
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The mechanism in which exercise prevents the onset of AD is not well understood.
Recent research utilizing human patients with AD wanted to determine whether exercise could
increase the quality of life in individuals suffering from AD. Forty patients aged between 65 and
75 years old participated in this study. Similar to the study utilizing the Tg2576 AD mouse
model, participants were split into an experimental group in which participants performed
aerobic exercise three times a week over a span of sixteen weeks. The control group did not
undergo any form of exercise through the duration of the experiment. Both groups were
subjected to testing both before and after the 16-week treatment period; testing included blood
samples used to assess interleukin-6 (IL-6) and TNF-α, both of which are pro-inflammatory
cytokines commonly found in AD brains, psychological well-being tests, and an assessment of
each patient’s quality of life. After 16 weeks, participants in the experimental group showed
reductions in IL-6 as well as TNF-α, indicating that exercise may reduce inflammation involved
in AD development. Additionally, participants in the experimental group showed decreased pain
levels, decreased levels of depression, and an increase in overall mental health, indicating an
overall better quality of life. Individuals in the control group did not show significant reductions
in IL-6 or TNF-α and additionally did not show an overall better quality of life (Abd El-Kader et
al., 2016). Ultimately, this research shows the beneficial role of exercise in individuals with AD;
that exercise can prevent the inflammatory cycle in patients with AD and can even increase the
patient’s overall quality of life.
Because the research thus far has shown that exercise can actively reverse the
inflammatory response in the brain, exercise can be used to prevent this inflammatory cycle,
actively preventing AD onset. Further research is necessary to understand the appropriate
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amount of exercise necessary to prevent AD onset; however, thus far, the research has implicated
the necessity of exercise, which can be a useful tool in combating AD onset.
Like exercise, social interaction has shown to have protective effects against AD development.
Unfortunately, as people age, people are bound to become more socially isolated, due to the
death of friends and family. A lack of social interactions has a detrimental effect on an
individual’s mental health and behavior (Hsiao et al., 2018). Animal research has repeatedly
shown that a lack of social interaction exacerbates cognitive decline, including memory deficits,
in animal models of AD. Thus, aiming to maintain social interactions is beneficial in mitigating
the development of AD.
One study utilizing 126 Long-Evans hooded rats, which were split up into either control
or socially isolated (SI) groups (Frisone et al., 2002). SI groups were placed in isolation for six
hours per day over a twenty-one day period. Not only was this short-time period enough to raise
stress levels in SI rats, but SI rats also had longer latencies when trying to locate a platform in the
Morris Water Maze, a common task used to assess spatial memory. Ultimately, the findings
from this study indicate that temporary isolation (6 hours per day over 21 days) is enough to
impair spatial memory, further indicating the detrimental effects of social isolation.
Additionally, another study showed that SI can induce an inflammatory response in the brain,
while simultaneously reducing anti-inflammatory agents. Forty rats were divided into four
different groups: control socialized group, AD socialized group, control isolated group, and AD
isolated group (Ali et al., 2017). After four weeks, the rats were sacrificed and brains were
assessed for AB content and brain inflammatory factors, namely IL-1β and TNF-α. The isolated
control group showed significantly more AB content in comparison to the socialized control
group. The AD isolated group showed significantly more AB content in comparison to the AD
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socialized group. Thus, the results indicate that social isolation plays a strong role in furthering
the progression of AD. In addition, the isolated control group showed increased levels of IL-1β
and TNF-α in comparison to the socialized control group; the AD isolated group showed
increased levels of IL-1β and TNF-α in comparison to the AD socialized group. Ultimately, the
results show that social isolation increases the inflammatory response in the brain, furthering the
progression of AD (Ali et al., 2017). Ultimately, these findings indicate that social isolation has
detrimental effects on the brain and perpetuating the inflammatory cycle in the brain of AD
patients. Additionally, these findings point to the idea that socialization has protective effects in
preventing AD onset.
Thus far, studies have implicated that a lack of social interactions results in an increased
risk of developing AD. Additionally, reports have indicated that maintaining consistent social
interactions is beneficial in preventing the onset of AD. Research still needs to be conducted to
thoroughly understand the mechanism by which socialization is beneficial to delaying the onset
of AD, but it is currently understood that socialization does indeed play a protective role. One
study utilized a large group of women without dementia. The women’s social networks were
measured using a Lubben Social Network Scale (LSBS); women with larger social networks
were less likely to develop dementia over a four year follow up period in comparison to women
with smaller social networks. Unfortunately, establishing a solid link between social network
and cognitive function is relatively complex; however, given that a lack of social interactions
results in an increased and perpetuating inflammatory response in the brain of AD patients, it is
not unrealistic to hypothesize the maintaining social networks or increasing socialization may
have anti-inflammatory effects, and therefore, plays a protective role in preventing AD.
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Ultimately, it is understood that socialization does play a protective role, it is simply
difficult to link socialization with a anti-inflammatory response in the brain. Data has thus far
shown that a lack of social interactions leads to an increase in inflammatory factors, namely IL1β and TNF-α. Thus, if a lack of social interaction leads to an increased inflammatory response,
and it is additionally understood that social interactions play a protective role in preventing AD
onset, social interactions may very well actively prevent or reduce the inflammatory cycle that is
present in AD brains.
The food we consume plays an integral role in maintaining our health and well-being.
Certain diets can interestingly be used to prevent the onset of certain diseases and can even be a
treatment option in various diseases. For example, the ketogenic diet, which is a high-fat, lowcarbohydrate diet, was developed as a treatment method for individuals suffering from epilepsy.
Additionally, gut health has recently become a popular topic in diet culture, likely due to the
concept that a healthy gut results in healthy weight loss. Gut health is an important health topic
because the foods we consume allow us to maintain healthy lifestyles, preventing the onset or
progression of disease. One diet has recently become a popular diet that has potential benefits in
preventing the onset of AD: the Mediterranean diet.
The Mediterranean diet is a way of eating consistent with the foods consumed in the
islands surrounding the Mediterranean Sea. This diet was initially developed to combat coronary
heart disease, because researchers noticed that people living in these areas and consuming the
traditional cuisine in these particular islands were at a lower risk for developing coronary heart
disease. This diet consists of vegetables, fruits, whole grains, beans, nuts and seeds, and olive
oil. Additionally, individuals properly following the Mediterranean diet rarely consume red meat
and occasionally drink small amounts of red wine. Those who choose to properly follow the
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Mediterranean diet should prepare their meals with plant-based foods as the main focus; for
example, fruits and vegetables should be consumed in high amounts, in contrast with meat,
which is more commonly the focus during meals. Unlike other diet fads, the Mediterranean diet
is one of the only diets that is endorsed by the Dietary Guidelines for America as well as the
World Health Organization (WHO) (Mayo Clinic, 2019). Thus, those aiming to live a healthier
lifestyle and decrease their risk of developing coronary heart disease may want to consider the
Mediterranean diet.
Along with this healthy diet’s ability to prevent the onset of coronary heart disease, this
diet has also been proved to ease inflammation in AD. Research concerning this diet has mainly
been conducted on the foods that make up the Mediterranean diet; for example, researchers now
understand that unsaturated fats inhibit oxidative stress and reduce inflammation while saturated
fats promote inflammation, mainly in the hypothalamus. Thus far, research has been mainly
focused on the beneficial aspects of single nutrients within the Mediterranean diet; however,
researchers are beginning to understand the overall benefits of consuming a Mediterranean diet
consistently, rather than the simple benefits of each individual food. The overall benefits of
consistently consuming a Mediterranean diet has shown to reduce cognitive decline and
inflammation, therefore ultimately reducing the risk of AD. Interestingly, MD promotes overall
brain integrity; individuals who closely adhere to this diet throughout their lifespan tend to
exhibit “greater brain volumes, slower rate of hippocampal atrophy, improved structural
connectivity, as well as less Aβ accumulation” (McGrattan et al., 2019), therefore lessening the
risk of developing AD.
The entire influence of a dietary pattern on neuroinflammation is not entirely understood;
however, the antioxidants present in fruits and vegetables likely suppress the neuroinflammatory
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processes by inhibiting free radicals, which are produced by activated microglial cells. An
overwhelming amount of free radicals results in oxidative stress, which causes aging and a range
of diseases. Flavonoids are found in plants and are consumed in great quantities in individuals
who properly follow the Mediterranean diet. Flavonoids play a protective role in preventing AD
by fighting toxins, such as free radicals, and therefore prevent neuroinflammation. Additionally,
flavonoids likely inhibit pro-inflammatory cell signaling pathways. Consumption of fats, mainly
in the form of olive oil and fish, reduces the expression of pro-inflammatory cytokines
(McGrattan et al., 2019).
Ultimately, the single nutrients in a Mediterranean diet all possess anti-inflammatory
properties; however, the overall consistent consumption of a Mediterranean diet may show
greater anti-inflammatory properties in the brain, in comparison to continued consumption of a
single nutrient within this diet. The anti-inflammatory properties within the Mediterranean diet,
which lessen the risk of AD development, lend to the significance of leading a healthy lifestyle.
This diet, along with consistent exercise and adequate socialization, actively allow for an
arguably happier, healthier lifestyle, which ultimately will lead to a lessened risk of AD
development. These simple lifestyle choices can make a huge and lasting impact on an
individual’s physical and mental well-being and should be heavily considered, if individuals
want to lead a healthy lifestyle and mitigate the risk of AD.
As important as it is to follow a healthy diet, such as the Mediterranean diet, to delay or
prevent the onset of AD, it is similarly important to maintain a healthy weight. Obesity has
become a prevalent issue, especially across the U.S. Unfortunately, obesity has been linked to a
range of chronic illnesses, such as type 2 diabetes, cardiovascular disease, and cancer
(Pegueroles et al., 2018). Additionally, obesity has been linked to dementia and AD.
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Interestingly, mid-life obesity has more specifically been directly linked to AD, whereas late-life
obesity studies have been largely inconclusive, but some studies have determined that late-life
obesity may be protective against AD (Pegueroles et al., 2018). More research needs to be
conducted to understand the linkage between AD and obesity; however, it remains clear that
maintaining a healthy weight could play a protective role against AD onset.
Interestingly, obesity promotes many the same pro-inflammatory processes that are
present in the brain in individuals with AD. As a result of obesity, adipocytes, or fat cells,
enlarge and spill their contents into their immediate vicinity, which triggers a pro-inflammatory
response. Cytokines and chemokines are drawn to this site of inflammation, further augmenting
this pro-inflammatory cycle. Similarly, just as exercise promotes the conversion from proinflammatory M1 to anti-inflammatory M2, the rapidly increasing number of macrophages,
cytokines, and chemokines at the site of inflammation promote pro-inflammatory M1 microglia,
furthering this pro-inflammatory cycle. Additionally, TNF-α, a pro-inflammatory cytokine, is
actually correlated with body mass index (BMI); research has shown that there is an increase of
TNF-α obese individuals in comparison to healthy controls (Letra et al., 2014). Unfortunately,
the inflammation resulting from obesity is chronic, meaning that this pro-inflammatory cycle
continues until weight loss occurs.
Additionally, obesity has been shown to cause cognitive impairments. It has been
hypothesized that these cognitive impairments arise due to the continued inflammation that
occurs as a result of obesity. These cognitive impairments affect memory, attention, increased
impulsivity, poor organization, and poor planning abilities (Spyridaki et al., 2016), all of which
are impaired in AD.
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Research surrounding the importance of sleep began between the 1960s and 1970s. The
use of electroencephalogram (EEG) allowed researchers to discern distinct patterns of sleep,
leading to the classification of stages of sleep, ultimately allowing for the healthcare practitioners
to diagnose and treat specific sleep disorders (Worley, 2018). Even more recently, researchers
have focused on the deficits that occur as a result of sleep deprivation. It has been uncovered
that sleep disruptions have a direct link to hypertension, impaired immune functioning, mood
disorders, and of course, AD. Despite the prevalent research regarding the importance of sleep
to prevent the onset of harmful diseases, inadequate sleep continues to threaten the health of
everyday people. David F. Dinges, PhD, Professor and Chief of the Division of Sleep and
Chronobiology in the Department of Psychiatry at the University of Pennsylvania Perelman
School of Medicine, points out that “People have come to value time so much that sleep is often
regarded as an annoying interference, a wasteful state that you enter into when you do not have
enough willpower to work harder and longer” (Worley, 2018). Sleep contributes to our wellbeing; thus, it is important to prioritize sleep, rather that dismiss sleep as a nuisance.
Most people understand that sleep is beneficial and that everyone should aim for at least
six hours of sleep per night; however, many people struggle to initiate sleep and to then remain
asleep. Unfortunately, “nearly half of adults older than 60 years of age have difficulty initiating
and maintaining normal sleep patterns” (Irwin & Vitiello, 2019), which places these individuals
at a greater risk of developing AD among other chronic illnesses. Interestingly, many
researchers assumed that sleep disturbances resulted from AD; however, it appears that sleep
disturbances actually may contribute to AD onset. Additionally, without sleep, the hippocampus
is unable to form new memories; these same processes are impaired in individuals with AD.
Essentially, our sleep is governed by circadian rhythms; these activities are commonly impaired
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in individuals with AD. Additionally, when these activities are impaired, individuals have an
increased risk of mild cognitive impairment (MCI), which can lead to AD. Overall, weaker
circadian rhythm activities are associated with poor cognitive function (Uddin et al., 2020).
It is currently understood that sleep deprivation also leads to pro-inflammatory processes,
which are involved in the onset and progression of AD. Several sleep analyses have
demonstrated that even just one night of partial sleep leads to an increase in inflammatory
processes, leading to the continued production of inflammatory cytokines. Interestingly enough,
too much sleep has also been shown to increase inflammatory processes and has been shown to
specifically increase IL-6, an inflammatory cytokine (Irwin & Vitiello 2019). Thus, it is
understood that sleep disturbances are directly linked to increased inflammatory and ultimately
the development of chronic diseases, and can therefore be classified as a risk factor for AD onset.
More specifically, it has been shown that chronic sleep deprivation activates microglia mainly in
the hippocampus, causing the increased production of pro-inflammatory cytokines. In
chronically sleep deprived individuals, interleukin-1β, tumor necrosis factor-α, and nitric oxide
were increased and positively correlated amyloid deposition in the brain (Lucey, 2020).
Ultimately, more research is needed to more thoroughly understand the associated risk of
sleep deprivation and AD onset. Because sleep deprivation can lead to pro-inflammatory
processes, and even hinder memory formation, specifically in the hippocampus, it is clear that
sleep deprivation is directly linked with AD onset. It is not well understood whether adequate
sleep reduces these inflammatory processes, because unfortunately, individuals with AD tend to
have sleep disturbances, perpetuating the cycle of inflammation involved in AD. Maintaining a
consistent, good sleep schedule, aiming to acquire at least six hours of sleep, could potentially
delay the circadian rhythm deficits that so commonly occur as a result of aging.
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The glial-lymphatic system, more commonly known as the glymphatic system, is a newly
recognized mechanism in the brain that contributes to the removal of neurotoxins, similarly to
the idea that the lymphatic system works to breakdown or remove toxins from the body. More
specifically, the glymphatic system allows for the rapid exchange of CSF and interstitial fluid
(Jessen et al., 2015). Unlike the lymphatic system, which shows increased function when awake,
the glymphatic system seems to be hard at work specifically while an individual sleeps (Jessen et
al., 2015). Because the glymphatic system allows for the removal of neurotoxins, the glymphatic
system has recently become the focus for researchers interested in neurodegenerative diseases,
including AD. Interestingly, Iliff et al. discovered that the glymphatic pathway is responsible for
clearing beta amyloid plaques, a marker of AD (Jessen et al., 2015). Additionally, a single night
of sleep deprivation resulted in a significant increase in amyloid-B burden (Mestre et al., 2020)
further indicating the significant role that the glymphatic system plays in controlling and
preventing the accumulation of AB plaque deposits. Individuals who sleep less and less tend to
show less glymphatic system functioning, given that the glymphatic system works at an optimal
level while an individual sleeps. Given that sleep deprivation has recently been classified as a
contributor to AD onset and the glymphatic system optimally functions to clear AB plaques
while an individual sleeps, it is imperative to find or create a diagnostic tool that can be used to
assess glymphatic function in individuals who may be at risk of developing AD.
Overall, it is important to maintain a healthy lifestyle in order to prevent the onset of a
range of chronic illnesses, including AD. A disturbance in any of the aforementioned aspects of
a daily lifestyle can lead to increased inflammation, and place individuals at a further risk of
developing AD. Small lifestyle changes, such as eating a healthy diet, maintaining a healthy
social life, and getting adequate sleep could have a huge impact on an individual’s well-being
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and could be the difference between acquiring AD, a progressive and deadly disease.
Ultimately, individuals should aim to eat healthy, socialize, and get adequate sleep to prevent the
onset of chronic illnesses, such as AD.
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Future Research/Plans for Treatment
Although an official diagnosis of AD can mainly be confirmed from an autopsy upon the
discovery of Aβ plaque accumulation, there are ways to determine whether an individual may be
suffering from AD prior to an official diagnosis from an autopsy. Thus, it is vital that
researchers determine different ways to predict the onset of AD to start proactive treatment or
offer options for patients to improve their lifestyle, such as exercising or eating a balanced diet.
Some warning signs are more obscure, in contrast with the common loss of memory that
is associated with AD. Interestingly, researchers have discovered that simply looking at writing
patterns can predict the onset of AD, even before symptoms have appeared (Kolata, 2021).
In a study conducted by IBM, the researchers looked at 80 males and females in their 80’s; half
of the participants suffered from AD, while the other half did not. Prior to half of the
participants’ development of AD, the researchers asked all participants to take an abundance of
cognitive tests as well as look at and subsequently analyze a picture of a boy reaching towards a
cookie jar. Through the participants’ writing, the researchers looked for subtle errors. More
specifically, the researchers looked for repetitive word usage, errors in capitalization, and
language that has “a simple grammatical structure, and…missing subjects and words like ‘the,’
‘is’ and ‘are’ (Kolata, 2021). The researchers predicted that the individuals who made small
errors and used simpler words were at a higher risk of developing AD; interestingly, the program
predicted which individuals would later be diagnosed with AD with 75% accuracy, indicating
that apparent AD symptoms appear well before an official diagnosis.
It is well-known that abnormalities with language occur as a result of AD; thus, this
research indicates that this change in language can be shown through an individual’s writing
skills as well. This study is extremely valuable; AD is a progressive and degenerative disease;
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thus, finding a method for earlier diagnosis can provide a huge impact in a patient’s
prognosis. Through early detection of AD, healthcare providers are better able to advise their
patients to make important lifestyle changes that can allow them to at least delay the progression
of AD.
The need for future AD research is evident; AD places an economic as well as emotional
burden on patients and families. When faced with the devastating news of an AD diagnosis,
family members feel they have already lost a loved one, due to the inevitable outcome of the
disease. Additionally, AD is a progressive and deadly disease and current therapies are unable to
reverse the path of the disease. Additionally, given the fact that the baby boomer population is
aging, more and more people will likely face an AD diagnosis, given that the greatest risk factor
of AD is aging. Ultimately, future research is necessary to aid in finding a cure for
AD. Approximately 90% of AD clinical trials fail; however all of these trials were able to
provide data in regards to the various mechanisms involved in the progression of the
disease. More clinical trials are currently underway, but according to the National Institute of
Aging, “Currently, at least 270,000 volunteers are needed to participate in about 200 active
clinical trials and studies that are testing ways to understand, diagnose, treat, and prevent
Alzheimer’s disease” (Alzheimer's disease fact sheet, 2019). Additionally, all different types of
volunteers are needed; “studies need participants of different ages, sexes, races, and ethnicities to
ensure that results are meaningful for many people” (Alzheimer's disease fact sheet,
2019). Participating in various trials is one way to fight against the disease; research cannot be
conducted without adequate volunteers and other resources. It is necessary to have a large
number of participants in various AD studies, because many people with AD tend to suffer from
other medical conditions, making it difficult to comply with the clinical trial protocols and older
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participants are more likely to die (Alzheimer’s disease clinical fact sheet, n.d). Thus, adequate
participation is required in many AD studies and could allow for a more thorough understanding
of the disease and its progression as well as provide insight to different mechanisms that should
be targeted through the use of various therapies.
Various therapies are undergoing clinical trials right now. Currently, “One class of
medications that is currently being developed are inhibitors of the beta-site amyloid precursor
protein cleaving enzyme (BACE inhibitors). These compounds inhibit the enzyme β-secretase,
which is responsible for producing the β-amyloid protein that is responsible for the plaque
formation in AD” (Jadoopat, 2019). These compounds were initially introduced, because
evidence showed that “a rare human mutation at the BACE1 cleavage site of APP rseults in a
40% decrease in Aβ production” (Das & Yan, 2019), suggesting that this mutation is protective
against AD onset. Additionally, APP is processed in one of two pathways. Through the
amyloidogenic pathway, APP is cleaved by BACE1, resulting in the production of precursors of
Aβ; inflammation causes an increase in BACE activity, ultimately resulting in increased Aβ
plaques (Evin, 2016). According to Das and Yan, recent trials for BACE1 inhibition have been
able to lessen Aβ production and improve cognitive deficits (Das & Yan, 2019). Additionally,
phase 1 trials showed that up to 95% of β-amyloid protein was reduced within the cerebrospinal
fluid (Jadoopat, 2019). These results are promising and suggest that current clinical trials may
soon be able to produce a BACE1 inhibitor, which will be well tolerated, safe, and effective at
reducing Aβ accumulation.
Biogen recently created a drug called aducanumab, which has been created to target βamyloid by binding to the aggregated Aβ plaques. Aducanumab is then thought to be able to
reduce the number of Aβ plaques in the brain, therefore slowing disease progression (Flavell,
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2020). Although aducanumab is unable to reverse the path of the disease, slowing the
progression can ease the devastation that patients and families often face as a result of an AD
diagnosis. Additionally, as a result of the slower progression of the disease, families will likely
not have to rush to find proper care for the individual suffering from AD. Aducanumab will
allow families to sit down with their loved one to discuss options more thoroughly, allowing the
patient to have more autonomy, which can help to preserve family relations.
After my grandmother was diagnosed with AD, her disease progressed quickly. Within a
few weeks of her diagnosis, her children had to remove her driving privileges by taking her car
keys. Additionally, my grandmother was moved to a memory care unit within the retirement
facility at which she already resided. To my grandmother, she felt completely blindsided. She
became especially angry with my family and claimed she was capable of driving and did not
want to move to a separate unit. My nana likely felt betrayed and hurt that her own family did
not allow her to make any of these decisions for herself. In all reality, my family was looking
out for her best interests; we wanted her to be safe and cared for, but to my grandmother, she
likely felt frustrated that these decisions had been made and communicated with the retirement
facility staff, even though she did not agree with these decisions.
Fortunately, aducanumab will allow for a slowing of the progression of the disease,
which will not only ease cognitive symptoms associated with the disease, but also allow families
to have important discussions, such as removing a patient’s driving abilities or moving their
home to an area where they can receive proper care. Additionally, Biogen’s current tests with
aducanumab show that participants “saw an increased ability to manage finances, do chores
around the house, go shopping, and leave the home independently” (Aducanumab: Benefits,
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Side-Effects & status of clinical trials, 2020). Thus, this drug does much more than alleviate
symptoms associated with AD; it allows patients to retain their independence.
Along with the importance of decreasing the amount of Aβ plaques in an AD brain to
relieve various cognitive symptoms associated within the disease, there is evidence that
“suggests that brain tissues in AD patients are exposed to oxidative stress during the
development of the disease. Oxidative stress or damage such as protein oxidation, lipid
oxidation, DNA oxidation, and glycoxidation is closely associated with the development of
Alzheimer's disease” (Feng & Wang, 2012). Additionally, oxidative stress has been shown to act
as secondary messengers in inflammation, indicating that reducing oxidative stress could reduce
inflammation and therefore relieve and ideally improve AD symptoms (Stuchbury & Münch
2005). A variety of drugs, called multitarget-directed ligands (MTDLs) have been reintroduced
to the realm of AD research. These drugs have the ability to act “at the various
neuropathological levels of AD” (Simunkova et al., 2019), which could be beneficial given that
AD is the result of various mechanisms in the brain. Ideally, attacking different
neuropathological levels will allow for effective symptom relief and could even induce a reversal
of the course of disease.
Current therapies for AD include AChE inhibitors such as galantamine, donezapil and
rivastigmine, which mainly treat the symptoms of AD. Because there currently are few therapies
marketed for AD patients and because the incidence of AD will likely increase over time, new
and effective therapies are necessary. First and foremost, researchers should aim to encourage
more people to participate in various clinical studies. These clinical trials require a lot of effort
from both the researchers and the participants, but the overall outcome of contributing to AD
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research and ideally finding a cure can ideally encourage people to participate. A lack of
participants could result in an insufficient amount of evidence to produce definitive results.
Additionally, because age is the main risk factor associated with AD, it is more likely that
participants will die over the course of a clinical trial. Thus, an even greater amount of
participants is required for AD research in comparison to other clinical trials that study the
effects of various therapies in disease that are not limited to the geriatric
population. Additionally, there are several different paths that healthcare professionals and
researchers could analyze to develop future therapies, making it challenging for researchers to
determine which path or level of the disease should be targeted. It would be most ideal for a
drug to attack at different neuropathological levels for effective symptom relief and even a
reversal of the course of disease, such as through studies involving MTDLs. Currently, it
appears that the most likely drug to enter the market will be Biogen’s aducanumab. Results from
phase 2 trials indicated that “all doses of aducanumab (given as monthly infusions into the
bloodstream) significantly reduced amyloid plaques in the brain in a time- and dose-dependent
manner” (Flavell, 2020). The use of this particular drug has shown encouraging results,
promising to retain a patient’s independence. Ultimately, any drug that has the ability to
alleviate AD symptoms, improve cognitive function, and most ideally, reverse the path of disease
provides hope to AD patients and families.

62

Conclusion
Life is unpredictable; we will never know what the future holds, in regards to our health.
The conundrum of our health, including the etiology and pathology of AD have been long
studied and analyzed by philosophers and other great intellects. Even today, medical
professionals and researchers do not have a complete and full understanding of AD, suggesting
that the complexity of the disease has posed a challenge to researchers and scientists likely for
centuries, even before the term ‘Alzheimer’s disease’ had been coined. In more recent years,
many researchers have dedicated their lives to finding a cure or other treatment options to help
people suffering from AD. The few marketed treatment options as well as the high incidence of
AD in the geriatric population emphasize the idea that AD research is important and necessary.
Although much is still unknown about the pathology and etiology of AD, new discoveries
are being made each day. For example, it is now common knowledge that Aβ plaques and senile
tangles result from, as well as contribute to, the neuroinflammation involved in AD, suggesting
that the progression of AD occurs as a result of various cyclical proinflammatory pathways.
These proinflammatory pathways can be induced by a variation of genetic factors and unhealthy
lifestyle choices. Thus, individuals should aim to make healthy lifestyle choices, thereby
lessening the chance of developing chronic or even terminal illnesses, including AD. For
example, individuals who follow a Mediterranean diet, sleep an adequate amount each night,
exercise daily, and socialize have a lesser likelihood of ever developing AD in comparison to
individuals who follow a different, more unhealthy lifestyle. However, leading a healthy
lifestyle does not entirely protect someone from developing chronic illnesses, such as AD. My
grandmother, for example, was an extremely healthy individual. She always maintained a
healthy weight, ate mostly nutritious, whole foods, and was fairly active throughout her life.
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Unfortunately, sometimes AD and other illnesses seem to just appear, as a sort of cruel game of
chance. This is another example of why more research is needed to fully understand and treat
AD.
It is important that patients and families retain the faith that a cure or beneficial
treatments will be produced; given the high incidence of AD in the geriatric population, the
discovery of new drugs and alternative treatment methods have been long studied. Although
there have many numerous treatment failures over the course of several decades, these failures
have furthered researchers’ desire to continue their search. Many researchers have explained that
these failed treatments have in a way, humbled them, allowing them to better appreciate the
complexity of the disease. Failed treatment have also allowed researchers to discovery the
mechanisms involved within these proinflammatory pathways. For example, researchers
understand that the use of multiple drugs may be the more effective method used to find a cure
for AD. Because the pathways involved in AD are so complex, no one drug thus far has been
able to cease or reverse the progression of the disease, suggesting that multiple proinflammatory
pathways should be targeted.
Researchers have become more optimistic recently, especially considering Biogen’s
current development of aducanumab. This drug promises to slow the progression of AD,
allowing individuals to maintain autonomy and independence. This drug marks a major
breakthrough, given that roughly 99% of drug trials fail (Drugs Discovery Trends Editor, 2019)
by either low toleration of the medication or a lack of effectiveness. Thus, a beneficial AD drug
must be effective and tolerated well; it is challenging to create this type of AD drug, because of
the multiple pathways involved in inducing the inflammatory processes of the brain. It is
remarkable that Biogen and other companies are on the cusp of a breakthrough, discovering and
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producing beneficial treatments, which could change the lives of patients and families for the
better.
While my grandmother lived with AD, my family never gave up hope that a cure would
someday be found. Although my grandmother has now passed on, we still hope and pray for
new, reliable treatment options and ideally a cure. We understand how it feels to slowly lose a
loved-one due to AD. I have written this thesis to share a part of my life, my grandmother’s AD
diagnosis, as well as generate a guide for individuals who are struggling or know someone else
who may be struggling with an AD diagnosis. With the care, compassion, and understanding of
this devastating disease from a medical, familial, and introspective point of view, I believe that a
cure will one day be found, ending the panic and dread that accompanies an AD diagnosis.
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